Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Qiyan Cai
Observed name:
Qi-Yan Cai
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Army Medical University,
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0009-0009-4299-8511
Observed ORCID:
0009-0009-4299-8511
OpenAlex ID:
A5100522037
Prostatic fluid exosome-mediated microRNA-155 promotes the pathogenesis of type IIIA chronic prostatitis
2021
·
Baixiong Zhao
, Jun Zheng
, et al.
·
Translational Andrology and Urology
·
13
PDF
Advances of catalpol's roles in the nervous system.
2010
·
Qiyan Cai
, Yao Zhong-xiang
·
Xiandai shengwu yixue jinzhan
·
4
The efficacy and safety of gemcitabine and docetaxel in pseudomyogenic hemangioendothelioma: a multi-center experience
2025
·
Qiyan Cai
, Bushu Xu
, et al.
·
BMC Cancer
·
3
PDF
Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis.
2024
·
Xing Zhang
, Qiuzhong Pan
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Roles of PTEN in Neuronal Injury and Brain Disorders
2010
·
Qiyan Cai
·
Medical Recapitulate
·
1
Supplementary Table S4 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S6 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S7 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S4 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S3 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S2 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S3 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S5 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S2 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Data from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S5 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Figure S1 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Supplementary Table S1 from Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
Long-term Results of Multiantigen Stimulated Cell Therapy I, Alone or in Combination with Chemotherapy, as First-line Maintenance Therapy in Advanced Sarcoma: A Multicenter, Phase I Trial
2026
·
Xing Zhang
, Bushu Xu
, et al.
·
Clinical Cancer Research
Expression pattern of Id2 in the corpus callosum of developmental and remyelinated rat brain
2011
·
XingShu Chen
, Wenqin Cai
, et al.
·
Neuroscience Research
Roles of Neutral Endopeptidase in Tumor Suppression
2009
·
Yunchao Wang
, Wu HongRi
, et al.
·
Xiandai shengwu yixue jinzhan
[Advances of tumor suppressor PTEN in the nervous system].
2007
·
Qi-Yan Cai
, Zhong-Xiang Yao
·
PubMed
Show more works
View as search
Works count:
22
Citation count:
22
H-index:
3
I10-index:
1
Year
Topic
Type